Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 87

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 87
---
 The terms of any financing may adversely affect the holdings or the rights of our stockholders. If we are unable to obtain funding we could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business operations. The audited consolidated financial statements for December 31, 2024, have been prepared on the basis that we will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability for us to continue as a going concern. Cash Flows The following table summarizes our cash flows for the periods presented:

|                                                      |     | Year Ended December 31, |        2024 |   |     |   |       2023 |   |
|:-----------------------------------------------------|:----|:------------------------|------------:|:--|:----|:--|-----------:|:--|
| Net cash used in operating activities                |     | $                       | (18,321,276 | ) |     | $ | (7,286,286 | ) |
| Net cash used in investing activities                |     |                         |     (19,171 | ) |     |   |          — |   |
| Net cash provided by financing activities            |     |                         |  12,847,764 |   |     |   | 14,025,008 |   |
| Net (decrease) increase in cash and cash equivalents |     | $                       |  (5,492,683 | ) |     | $ |  6,738,722 |   |

Net Cash Used in Operating Activities During the year ended December 31, 2024, net cash used in operating activities was $18.3 million, which consisted of a net loss of $15.0 million and a net change of $3.4 million in our net operating assets and liabilities. During the year ended December 31, 2023, net cash used in operating activities was $7.3 million, which consisted of a net income of $0.1 million and a net change of $8.1 million comprised of the change in fair value of the warrant liability, stock -basedcompensation expense and depreciation expense, offset by a net change of $1.0 million in our net operating assets and liabilities. Net Cash Used in Investing Activities During the year ended December 31,